MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$34,598,126
Proceeds from exercise of
common stock options,...
$1,999
Net cash provided by
financing activities
$34,600,125
Net increase in cash
and cash...
$8,980,422
Canceled cashflow
$25,619,703
Prepaid expenses and
other current assets
-$1,824,430
Stock-based compensation
expense
$1,797,676
Accounts payable
$284,542
Net cash used in
operating activities
-$25,619,703
Canceled cashflow
$3,906,648
Net loss
-$28,854,197
Accrued expenses
-$530,154
Change in fair value of
warrants
-$142,000
Back
Back
Cash Flow
source: myfinsight.com
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)